The Latest on the Intracept™ Procedure
Now Enrolling – the IMPROVE Study for the Intracept™ Procedure
Boston Scientific recently began enrollment in a new study – the Intracept Minimally-invasive PROcedure for VErtebrogenic back pain (IMPROVE) – to compile real-world outcomes of patients treated with the next-generation Intracept™ Access Instruments. The IMPROVE Study...
Boston Scientific Announces Positive Noridian Local Coverage Determination for the Intracept™ Procedure
Policy expands physician and patient access for vertebrogenic low back pain treatmentMARLBOROUGH, Mass., Feb. 22, 2024 – Boston Scientific Corporation (NYSE: BSX) has announced that Noridian Healthcare Solutions, a Medicare Administrative Contractor (MAC), published a...
Relievant Medsystems Announces Positive Coverage Policy from Humana for the Intracept Procedure
Third national coverage policy published in 2023 for proven vertebrogenic pain treatment MINNEAPOLIS – November 13, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Humana...
Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield
Expands access to vertebrogenic pain treatment for 36 million patients MINNEAPOLIS – October 3, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Anthem Blue Cross and Blue...
Relievant Medsystems Introduces Intracept Simulator System Powered by Medability for Improved and Expanded Physician Training Opportunities
Advanced technology enhances Intracept Procedure training for the treatment of vertebrogenic pain CHICAGO – IPSIS Annual Meeting – September 21, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back...
Relievant Medsystems Announces Pooled Analysis Demonstrating the Intracept Procedure Significantly Reduces Low Back Pain-related Healthcare Utilization
Findings show marked reductions in need for opioids and therapeutic lumbosacral spine injections five years post-procedure MINNEAPOLIS – September 12, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low...
Relievant Medsystems Announces Pooled 4-Year Outcomes Validating Long-Term Effectiveness of the Intracept Procedure
Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low Back Pain Minneapolis – July 20, 2023 – Relievant Medsystems, a company dedicated to transforming the...
Relievant Medsystems Introduces Next-Generation Access Instruments to Advance Intracept Procedure for Chronic Vertebrogenic Low Back Pain
Miami – ASPN Annual Conference – July 14, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the release of next-generation Intracept® Access Instruments. The new instruments...
Relievant Medsystems Announces Favorable Coverage Policy from Cigna Healthcare for the Intracept Procedure
MINNEAPOLIS – June 20, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced today that Cigna Healthcare, a health benefits provider for 19 million Americans, has established national...
Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients
MINNEAPOLIS – June 15, 2023 – Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the publication of three-year pooled results from two prospective clinical trials that further validate...